The case for and concerns about continuous dopamine stimulation in Parkinson’s disease

  • J. G. Nutt
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 27)


Delivery of levodopa or other dopaminergic agents to the striatum is a critical determinant of the clinical response and may account for many of the fluctations in response (“on-off”). This should be manageable with innovative delivery systems for the drugs. However further studies are required to determine if continuous dopaminergic stimulation will be complicated by increased levels of drug metabolites or down regulation of dopaminergic neurotransmission.


Large Neutral Amino Acid Dopaminergic Agent Plasma Levodopa Continuous Dopaminergic Stimulation Plasma Dopa Level 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Castro R, Abreu P, Calzadilla CH, Rodriguez M (1985) Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval. Psychopharmacology 85: 333–339PubMedCrossRefGoogle Scholar
  2. Cotzias GC, Papavasiliou PS, Tolosa ES, Mendez JS, Bell-Midura M (1976) Treatment of Parkinson’s disease with apomorphines: Possible role of growth hormone. N Engl J Med 294: 567–572PubMedCrossRefGoogle Scholar
  3. Direnfeld L, Spero L, Marotta J, Seeman P (1978) The L-Dopa on-off effect in Parkinson’s disease: Treatment by transient drug withdrawal and dopamine receptor resensitization. Ann Neurol 4: 573–575PubMedCrossRefGoogle Scholar
  4. Gancher ST, Nutt JG (1987) Diurnal responsiveness to apomorphine. Neurology 37: 1250–1253PubMedCrossRefGoogle Scholar
  5. Gervas JJ, Muradas V, Bazan E, Aguado EG, de Yebenes JG (1983) Effects of 3-OM-dopa on monoamine metabolism in rat brain. Neurology 33: 278–282Google Scholar
  6. Hardie RJ, Lees A J, Stern GM (1984) On-off fluctuations in Parkinson’s disease: a clinical and neuropharmacological study. Brain 107: 487–506PubMedCrossRefGoogle Scholar
  7. Hardie RJ, Malcolm SL, Lees AJ, Stern GM, Allen JG (1986) The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson’s disease who exhibit on-off fluctuations. Br J Clin Pharmacol 22: 429–436PubMedCrossRefPubMedCentralGoogle Scholar
  8. Juncos J, Serrati C, Fabbrini G, Chase TN (1985) Fluctuating levodopa concentrations and Parkinson’s disease. Lancet 2: 440PubMedCrossRefGoogle Scholar
  9. Kaye J A, Feldman RG (1986) The role of L-dopa holiday in the long-term management of Parkinson’s disease. Clin Neuropharmacol 9: 1–13PubMedCrossRefGoogle Scholar
  10. Kurlan R, Rubin A J, Miller C, Rivera-Calmlim L, Clarke A, Shoulson I (1986) Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 20: 262–265PubMedCrossRefGoogle Scholar
  11. McDowell RH, Papavasiliou P, Sweet R (1979) Long-term study and the effect of human growth hormone in parkinsonian patients treated with L-dopa. Adv Neurol 24: 475–488Google Scholar
  12. Muenter MD, Sharpless NS, Tyce GM, Darley FL (1977) Patterns of dystonia (“I-D-I” and “D-I-D”) in response to L-dopa therapy for Parkinson’s disease. Mayo Clin Proc 52: 163–174PubMedGoogle Scholar
  13. Nutt JG (1986) Food interactions in parkinsonism. Neurol Consult 3: 1–4Google Scholar
  14. Nutt JG, Woodward WR (1986) Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 36: 739–744PubMedCrossRefGoogle Scholar
  15. Nutt JG, Woodward WR, Anderson JL (1985) Effect of carbidopa on pharmacokinetics of intravenously administered levodopa: implications for mechanism of action of carbidopa in the treatment of parkinsonism. Ann Neurol 13: 537–543CrossRefGoogle Scholar
  16. Nutt JG, Woodward WR, Carter HJ (1986) Clinical and biochemical studies with controlled-release Sinemet. Neurology 36: 1206–1211PubMedCrossRefGoogle Scholar
  17. Nutt JG, Woodward WR, Gancher ST, Merrick D (1987) 3-0-methyldopa and the response to levodopa in Parkinson’s disease. Ann Neurol 21: 584–588Google Scholar
  18. Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL (1984) The “on-off” phenomenon in Parkinson’s disease: relation to levodopa absorption and transport. N Engl J Med 310: 483–488PubMedCrossRefGoogle Scholar
  19. Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson’s disease. Lancet 1: 467–470PubMedCrossRefGoogle Scholar
  20. Pincus JH, Barry K (1986) Control of the “on-off” phenomenon with dietary manipulation. Ann Neurol 20: 149Google Scholar
  21. Post RM (1980) Minireview: intermittent versus continuous stimulation: effects of time interval on the development of sensitization or tolerance. Life Sci 26: 1275–1282PubMedCrossRefGoogle Scholar
  22. Quinn N, Parkes D, Marsden CD (1984) Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 34: 1131–1136PubMedCrossRefGoogle Scholar
  23. Reches A, Fahn S (1982) 3-0-methyldopa blocks dopa metabolism in rat corpus striatum. Ann Neurol 12: 267–271Google Scholar
  24. Reches A, Mielke LR, Fahn S (1982) 3-0-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 32: 887–888Google Scholar
  25. Rivera-Calmlim L, Dujovne CA, Morgan JP, Lasagna L, Bianchine JR (1970) L-dopa treatment failure: explanation and correction. Br Med J 4: 93–94CrossRefGoogle Scholar
  26. Sharpless NS, Muenter MD, Tyce GM, Owen CA (1972) 3-methoxy-4-hydroxyphenyl- alanine (3-0-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson’s disease. Clin Chim Acta 37: 359–369Google Scholar
  27. Shoulson I, Glaubiger GA, Chase TN (1975) On-off response: clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonism patients. Neurology 24: 1144–1148CrossRefGoogle Scholar
  28. Sweet RD, Lee JE, Spiegel HE, McDowell F (1972) Enhanced response to low doses of levodopa after withdrawal from chronic treatment. Neurology 22: 520–525PubMedCrossRefGoogle Scholar
  29. Tolosa ES, Martin WE, Cohen HP, Jacobson RL (1975) Patterns of clinical response and plasma dopa levels in Parkinson’s disease. Neurology 25: 177–183PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • J. G. Nutt
    • 1
  1. 1.Department of NeurologyOregon Health Sciences UniversityPortlandUSA

Personalised recommendations